Literature DB >> 26723915

COX-2 inhibitors: a novel strategy in the management of breast cancer.

Miłosz Regulski1, Katarzyna Regulska2, Wiesław Prukała3, Hanna Piotrowska1, Beata Stanisz4, Marek Murias5.   

Abstract

Cyclooxygenase-2 (COX-2) inhibitors are common anti-inflammatory drugs with pleiotropic, endogenous actions that could be useful in the management of breast cancer. Here, we provide a complete understanding of the biochemistry of COX-2 and discuss the various molecular mechanisms behind its increased expression in breast cancer. We also analyze the possible mechanisms responsible for the anticancer effect of COX-2 inhibitors and provide an overview of the available preclinical and clinical data on the use of COX-2 inhibitors in breast cancer. Finally, we describe a mathematical model of the relation between the structure and biological potency of promising new COX-2 inhibitors (trans-stilbenes) using a 2D quantitative structure-activity relationship (QSAR) technique.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26723915     DOI: 10.1016/j.drudis.2015.12.003

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  14 in total

1.  The synergistic effect of mefenamic acid with ionizing radiation in colon cancer.

Authors:  Seyed Jalal Hosseinimehr; Zahar Safavi; Sahar Kangarani Farahani; Zohreh Noaparst; Arash Ghasemi; Hossein Asgarian-Omran
Journal:  J Bioenerg Biomembr       Date:  2019-03-07       Impact factor: 2.945

2.  Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway.

Authors:  Ang Li; Ping Chen; Ye Leng; Jiuhong Kang
Journal:  Oncogene       Date:  2018-07-06       Impact factor: 9.867

3.  Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Authors:  Anne-Sophie Hamy; Sandrine Tury; Xiaofei Wang; Junheng Gao; Jean-Yves Pierga; Sylvie Giacchetti; Etienne Brain; Barbara Pistilli; Michel Marty; Marc Espié; Gabriel Benchimol; Enora Laas; Marick Laé; Bernard Asselain; Brice Aouchiche; Martin Edelman; Fabien Reyal
Journal:  J Clin Oncol       Date:  2019-01-31       Impact factor: 44.544

4.  Parecoxib inhibits glioblastoma cell proliferation, migration and invasion by upregulating miRNA-29c.

Authors:  Lin-Yong Li; Jie Xiao; Qiang Liu; Kun Xia
Journal:  Biol Open       Date:  2017-03-15       Impact factor: 2.422

Review 5.  The Anti-Inflammatory Effects of Vitamin D in Tumorigenesis.

Authors:  Wei Liu; Lei Zhang; Hui-Jing Xu; Yan Li; Chuan-Min Hu; Jing-Yan Yang; Mei-Yan Sun
Journal:  Int J Mol Sci       Date:  2018-09-13       Impact factor: 5.923

6.  Annexin A1 peptide and endothelial cell-conditioned medium modulate cervical tumorigenesis.

Authors:  Laila Toniol Cardin; Janesly Prates; Bianca Rodrigues da Cunha; Eloiza Helena Tajara; Sonia Maria Oliani; Flávia Cristina Rodrigues-Lisoni
Journal:  FEBS Open Bio       Date:  2019-03-05       Impact factor: 2.693

Review 7.  Targeting Inflammation to Improve Tumor Drug Delivery.

Authors:  Vasiliki Gkretsi; Lefteris C Zacharia; Triantafyllos Stylianopoulos
Journal:  Trends Cancer       Date:  2017-08-23

Review 8.  Chemistry and Pharmacology of Cyperaceae Stilbenoids: A Review.

Authors:  Csilla Zsuzsanna Dávid; Judit Hohmann; Andrea Vasas
Journal:  Molecules       Date:  2021-05-10       Impact factor: 4.411

9.  Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis.

Authors:  Zhi-Qiang Han; Hongwei Liao; Feng Shi; Xiao-Ping Chen; Hua-Cheng Hu; Ming-Qing Tian; Li-Hua Wang; Songmin Ying
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

10.  Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-γ-linolenic acid peroxidation dependent mechanism.

Authors:  Yi Xu; Xiaoyu Yang; Tao Wang; Liu Yang; Yu-Ying He; Keith Miskimins; Steven Y Qian
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.